1. Sweden Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Simris Group AB Class B

Simris Group AB Class B

0.12
SEK
+0.00
(-3.27%)
-0.03EPS
123.91MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.02
0.04
0.04
0.03
0.05
0.02
0.05
0.03
0.02
0.01
- -
- -
Basic EPS, GAAP
-0.4
-0.79
-1
-1.09
-0.93
-0.82
-0.22
-0.24
-0.17
-0.16
-0.1
-0.04
-0.03
Free Cash Flow per Basic Share
-0.49
-2.15
-1.76
-1.13
-0.87
-0.54
-0.17
-0.15
-0.28
-0.17
-0.05
-0.03
-0.02
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.65
2.58
3.1
2.08
1.33
0.85
0.4
0.15
0.12
0.07
0.01
- -
- -
Tangible Book Value per Share
0.44
2.4
2.96
1.95
1.26
0.79
0.38
0.15
-0.71
-0.34
-0.21
-0.14
-0.09
Basic Weighted Avg Shares
21
15
19
21
26
33
119
119
142
229
348
630
940
Sales/Revenue/Turnover
- -
- -
1
1
1
2
2
6
4
4
3
2
1
Operating Margin (%)
-15,436.36
-4,086.18
-2,582.82
-2,654.78
-2,975.2
-1,412.85
-1,093.91
-471.37
-604.34
-841.41
-1,201.18
-1,830.46
-1,918.21
Depreciation Expense
- -
1
2
3
3
3
3
6
7
14
15
14
14
Net Income, GAAP
-8
-12
-19
-23
-24
-27
-26
-28
-24
-37
-35
-27
-26
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-15,365.45
-4,167.51
-2,664.2
-2,698.05
-3,145.8
-1,544
-1,182.09
-462.05
-598.58
-856.8
-1,197.4
-1,660.12
-1,845.5
Working Capital
6
24
31
11
10
7
21
-3
-16
-5
-13
-9
-2
LT Debt
- -
7
6
6
4
3
3
2
2
1
1
1
- -
Total Equity
10
39
65
43
40
35
47
18
23
26
6
- -
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-48.73
-37.21
-42.55
-58.14
-71.98
-62.13
-86.39
-118.4
-153.37
-221.44
- -
- -

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
- -
- -
LT Borrowings
1
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
842
1,350
1,350
Market Capitalization
36
135
124

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
16
12
9
Cash, Cash Equivalents & STI
1
11
8
Accounts Receivable, Net
- -
- -
- -
Inventories
1
1
1
Total Current Liabilities
25
13
12
Payables & Accruals
- -
- -
- -
ST Debt
1
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-15.94%
-42.06%
-108.33%
Free Cash Flow
0.37%
8.72%
-12.67%
Net Income, GAAP
11.42%
3.97%
-22.52%
Sales/Revenue/Turnover
39.49%
15.76%
-44.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
1
1
3
2025
- -
1
- -
- -
2
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
-0.03
-0.02
-0.03
-0.1
2025
-0.01
-0.01
-0.01
-0.01
-0.04
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Daniel Kubitza
Full Time Employees
5
Sector
Health technology
Industry
Biotechnology
Address
Herrestadsvägen 24A Hammenhog SN Sweden 276 50
IPO Date
Apr 22, 2016
Website
simrisalg.se
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Simris Group AB (publ), established in 2010 and headquartered in Hammenhög, Sweden, operates as a biotechnology company focused on harnessing the potential of microalgae and cyanobacteria. The company identifies and extracts high-value, natural, biologically active compounds for diverse applications. Its core activities span the biopharmaceutical sector, notably developing proprietary Antibody Drug Conjugate (ADC) payloads for cancer treatments, alongside active ingredients for skincare and sustainable nutrition products. Simris Group cultivates these microorganisms in advanced photobioreactor facilities, optimizing production of specialized compounds. The company continues to offer plant-based marine Omega-3 EPA and DHA supplements, providing alternatives to conventional sources, and engages in B2B biomass sales.